All Comparisons
Semaglutide vs Tirzepatide
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
Semaglutide: ATirzepatide: A
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / Dual GIP-GLP-1 Agonist |
| Evidence Rating | A — FDA Approved | A — FDA Approved |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying promoting prolonged fullness, and redu... | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... |
| Half-Life | ~160–168 hours (~7 days) | ~5 days (116 hours) |
| Bioavailability | ~89% SC; lower oral bioavailability (requires empty stomach) | ~80% SC |
| Molecular Weight | ~4113.6 g/mol | ~4813.5 g/mol |
| WADA Status | Not Prohibited | Not Prohibited |
| Dosing | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day, Once weekly (SC); Once daily (oral) (Subcutaneous (weekly injection); Oral tablet available (Rybelsus)) | 2.5–15 mg/week, titrated every 4 weeks, Once weekly (Subcutaneous) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved (Ozempic, Wegovy, Rybelsus). Additional approvals: MASH with fibrosis (Aug 2025), oral 25 mg for weight management (late 2025). 135+ warning letters issued to GLP-1 compounders; proposed permanent ban on 503B GLP-1 compounding. | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.